(RTTNews) – Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on targeted and immuno-oncology therapeutics, announced Thursday updated positive data from the DisTinGuish Study of DKN-01 Plus Tislelizumab.
The company noted that DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer or G/GEJ.
The company presented the updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.’s anti-PD-1 antibody, and chemotherapy, in patients with G/GEJ at the European Society for Medical Oncology or ESMO Congress.
Leap Therapeutics announced positive initial data from the DisTinGuish study on September 13 based on 25 G/GEJ patients enrolled in the trial that showed DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy was well tolerated with compelling activity.
The results presented at the ESMO Congress included additional patient data stratified by tumoral PD-L1 expression levels based on visually-estimated combined positive score (vCPS), showing that robust objective clinical responses can be achieved from this combination regimen independently of PD-L1 expression.